Patent Grant
11033022
This invention relates to apparatus and methods for the micromanipulation of biological materials and in particular, apparatus and methodologies for use in the cryopreservation of biological materials including human and non-human oocytes, embryos, sperm, stem cells and blastocyst.
Whilst the invention has been developed and has application in a wide range of micromanipulation situations and techniques with a range of biological materials, it finds particular application for use in the cryopreservation of human oocytes, embryos, morula, sperm and stem cells by vitrification as applied during In Vitro Fertilisation (IVF) procedures and the like.
The technologies involved and applied for cryopreserving of human and animal embryos are well established and with the application of suitable skill and know-how, the current technologies have achieved great improvement in the reliability and success in In Vitro Fertilisation procedures.
For the purposes of this specification, the term “freezing” and “vitrification” are taken to have the following definition:
“Freezing” is the cooling of a liquid to a solid state which may include crystalisation.
“Vitrification” is the cooling of a liquid to a solid state without crystalisation.
The techniques as understood and applied involve harvesting and cryopreservation of embryos, with a plurality of steps involving harvesting and extraction of oocytes, in vitro fertilisation thereof and the subsequent freezing and storing of such fertilised eggs and the resultant embryos and/or late stage blastocysts. The multitude of steps and handling stages required are heavily reliant on a high level of know-how and skill via the technical operators. The embryos or blastocysts once frozen, are then made available as required and can be thawed and transferred to the recipient whereby successful implantation to the uterus can result in normal development of a fetus and a resultant pregnancy.
More recently, such cryopreservation techniques have been successfully applied to unfertilised eggs and oocytes. Oocyte cryopreservation involves harvesting, freezing and storing of eggs or oocytes from a donor female in an unfertilised state. Such frozen eggs can then be drawn from a storage bank, thawed and made available for fertilisation and transferred to a donor on demand.
The techniques of cryopreservation as applied to oocytes rather than fertilised eggs and embryos, has certain ethical and medical advantages and has been subject to increased research and experimentation to improve the techniques involved.
The process of cryopreservation, particularly when applied to “live” biological materials, involves a high degree of trauma for the biological material in question, particularly having regard to the multiple handling steps required in accordance with current techniques. In addition to the trauma experienced as a result of physical handling, the biological material is also subject to potential ice crystal formation during freezing process, in addition to osmotic shock and toxic shock experienced during movement through a plurality of processing chemical solutions.
The traditional method of preparing frozen biological material includes the slow cooling of the material and its surrounding solution down to the storage temperature, with a view to deliberately initiating the formation of ice crystals remotely from the biological material per se. The traditional method is not optimal due to continuous formation of ice crystals. Alternative “vitrification” methods have been developed to address the ice crystal formation issues, however vitrification requires considerable technical skill for successful execution. Vitrification involves the transformation of the processing solution into a glass-like amorphous solid that is free from any crystalline structure, followed by extremely rapid cooling. The extremely rapid cooling is what enables the solution to achieve the glass-like amorphous state.
The application of either the traditional method of freezing or vitrification involves the use of chemical compounds and solutions, which are added to the biological material to minimise cell damage during the freezing processes. The chemical compounds and solutions are known as cryoprotectants and include permeating and non-permeating solutions. Permeating cryoprotectants are small molecules that readily permeate the membranes of the biological material with the formation of hydrogen bonds to the water molecules of the biological material with the aim of preventing ice crystallisation thereof. Examples of such permeating cryoprotectants are Ethylene Glycol (EG), Dimethyl Sulphoxide (DMSO) and Glycerol. At low concentrations in water, such permeating cryoprotectants lower the freezing temperature of the resultant solution and can assist in the prevention and minimisation of ice crystallisation. At higher concentrations which may differ at different cooling rates, such permeating cryoprotectants inhibit the formation of typical ice crystals and can lead to the development of a solid glass-like or vitrified state in which water is solidified prior to crystallisation or expansion. Toxicity of such permeating cryoprotectants increases with their increasing concentrations and is potentially toxic to the biological material in question and accordingly, the biological material must have minimal exposure to the permeating cryoprotectants over a very short period of time, or alternatively, exposure at a low temperature, whereby the metabolic rate of the biological material in question is reduced.
In contrast to the permeating cryoprotectants, the non-permeating cryoprotectants remain extracellular. Some examples of non-permeating cryoprotectants include disaccharides, trehalose and sucrose. The disaccharide cryoprotectants act by drawing free water from within the biological material and dehydrating the intracellular spaces. The resultant dehydration allows them to be used in combination with permeating cryoprotectants, such that the net concentration of the permeating cryoprotectant can be increased in the intracellular space. These techniques further assist the permeating cryoprotectant in preventing or minimising ice crystal formation.
During the vitrification process, permeating cryoprotectants may be added at a high concentration while the biological material's temperature is controlled at a predetermined level above freezing. However, because the toxicity of such high concentrations of permeating cryoprotectant can be substantial, it is not possible to retain the biological material at such temperatures for extended periods. Alternatively, a reduced time can be allowed for equilibrium after which the biological material, which may include oocytes or embryos are plunged directly into liquid nitrogen to effect freezing. The extremely rapid rate of cooling, minimises the negative effects of the cryoprotectant on the biological material and also, minimises ice crystal formation by encouraging vitrification.
The vitrification process involves exposing the biological material to at least three vitrification solutions. The vitrification solutions are typically added to successive wells in a multi-well culture dish, where the dish and solutions are warmed to a predetermined temperature, determined in accordance with the requirements of the biological material in question.
In a typical protocol, the biological material is physically transferred to a first solution in a first well and then washed by physically moving the biological material or cell through the solution in question with a cell pipetting device. The washing process is repeated in a second, third and fourth well over predetermined periods of time until the biological material or cell is considered ready for cryopreservation. The biological material is then physically drawn up with a predetermined amount of vitrification solution using a pipette or other handling device. A droplet containing the biological material or cell to be vitrified is then pipetted onto the vitrification device. The vitrification device is then physically transferred with the droplet and biological material attached and directly plunged into liquid nitrogen or placed onto the surface of a vitrification block that has been pre-cooled with liquid nitrogen. Once the biological material and the carrying fluid have become vitrified, the vitrification device is then inserted into a pre-chilled straw or other storage device, located in a slot in the vitrification block for subsequent transfer to long-term cold storage in either liquid nitrogen or liquid nitrogen vapour.
Various vitrification devices are used to manipulate the sample during the cryopreservation processes. Some propose a pipette style device in which the sample is sucked into a hollow tube which is then plunged directly into the solution or liquid nitrogen. Such device is marketed by Irvine scientific and sold as Cryotip®.
Other uses a loop/hook style device which will have a close loop or an open hook made from plastic or metal wire stuck to the end of a stem and is used to pick up the biological sample. Such devices are marketed by Cryologic under the trade name of fibreplug or Cryoloop as defined in WO00/21365.
Others tools as disclosed in international application WO 02/085110 “Cryotop” which is a flexible strip attached to a piece of plastic, in which the sample is placed on the strip and plunged directly into liquid nitrogen.
Current prior art requires many embryo handling steps using multiple apparatus; every handling step increases the chance of losing the embryo. It is estimated that 1-2% of embryos lost are contributed by handling during the vitrification step.
The trauma associated with the previously described processes and in particular the trauma imposed by repeated physical handing and manipulation of extremely delicate biological material including eggs, cells, embryos and blastocysts, impacts on the survival rate and hence the success, of the processes and methods previously described. Furthermore, the physical dynamics of a living embryo introduce rapid growing and changes to the shape of the embryo which further challenge any handling, and in particular, automated handling of such biological materials. Any automation needs to manage such dynamics as well as manage a range of different embryo types, rapid fluid movement along with a high range of fluid viscosities. Clearly, in order to maximise the chances of success and minimise trauma imposed on the materials being handled, it is highly desirable to reduce the physical handling of such delicate materials to an absolute minimum, in addition to minimising the number and degree of different washing solutions applied to the biological material.
Culturing is a technique to grow embryos to day 4, 5 or 6 post fertilisation to assist in the selection of the best quality embryos for transfer. Extended culture can increase the probability of a successful pregnancy.
One object of the invention is to provide improved apparatus and methods for the micromanipulation and storage of biological materials including but not limited to the culturing and cryopreservation of such materials.
Another object of the invention is to control the washing protocol times using automation and to reduce handling of the embryo, thus enabling full automation.
In a first aspect the invention provides an apparatus for micromanipulation of one or more biological materials, said apparatus including a vessel having a reservoir wherein said vessel has a channel formed in a portion of said reservoir, said channel including an intermediate restriction dimensioned to resist passage of said biological material but allow passage of liquid treatment solutions. The restriction can include a generally vertical passage or a generally horizontal platform. The intermediate restriction may include a physical narrowing of the passage, an orifice partially blocking the channel or one or more divots or other partial blocking means. The liquid treatment solution can include culture medium, cryopreservation medium, thawing medium, vitrification medium, fertilisation medium, or buffer solution.
The vessel preferably has an open top with the channel formed at the bottom thereof. The channel most preferably includes sub-reservoirs at either end of the restriction. The vessel is preferably formed of a material with high thermal conductivity and diffusivity with a particular preference for high conductivity in the sub-reservoir and channel regions. The vessel preferably includes a cap or lid adapted to seal the open top as either a separate lid or an integral hinged lid.
The apparatus may include a holder for said vessel.
The vessel or holder preferably includes a portion adapted to receive a bar code or other indicia.
The vessel material is preferably chosen from a material capable, of being sterilised and is biologically inert so as to pose no threat of contamination to the biological material/s. The vessel material preferably has high thermal diffusion and most preferably is between 1 mm and 0.05 mm thick.
In another aspect the invention provides an apparatus being an automated cryopreservation device including provision for one or a plurality of the vessels as previously described wherein the apparatus further includes means to irrigate the captive biological material with vitrification and/or other treatment solutions and means to vitrify the captive biological material.
In another aspect the invention provides a semi automated device including provision for one or a plurality of the vessels as previously described wherein the apparatus includes a means to irrigate the captive biological material with pre-vitrification or vitrification treatment solutions and fluidics to prepare the captive biological material for vitrification.
In another aspect the invention provides a method of cryopreservation of biological material comprising the steps of:
The series of vitrification solutions preferably includes gradually increasing non-permeating and permeating cryoprotectants selected from Ethylene Glycol (EG), Dimethyl Sulphoxide (DMSO), Glycerol, disaccharides, trehalose and sucrose to enhance the sinking of said biological material to the bottom of said sub-reservoir region so as to allow maximum drainage and retention of minimal irrigation solution prior to vitrification or freezing.
In another aspect the invention provides a method for pre-vitrification treatment of a biological material said method comprising the steps of:
In another aspect the invention provides a method of thawing a vitrified biological material and method comprising the steps of:
In another aspect the invention provides a method of storing a cryopreservation biological material comprising the steps of:
In another aspect the invention provides a method of thawing a frozen or vitrified biological sample comprising reversing the previously described method by using thawing solutions.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
The invention will now be described with reference to the Legend and Figures in the context of human in vitro fertilisation and the handling of biological material, being a fertilised human embryo, but the scope of the invention extends broadly to a wide range of micromanipulation techniques for biological material where the biological material in question can be conveniently handled and managed using the apparatus of the invention and made subject to a number of processing steps and procedures without being physically moved from the confines and security provided for by the apparatus of the invention.
In its broadest aspect, the invention provides a convenient holding vessel for receiving and securely holding a human embryo or other sample of biological material. The vessel 1 is formed as a unitary hollow bodied vessel having an internal reservoir 2. The vessel is preferably dimensioned to a small scale with the reservoir occupying the bulk of the vessel. The preferred small size of the vessel is particularly advantageous by allowing the miniaturisation and minimalisation of treatment solutions required for processing and vitrification of the biological material. The preferred volume for the treatment solutions is between 0.1 ul-100 ul, more preferably 0.5 ul-10 ul. The vessel preferably has an open top 5, giving direct access to the reservoir 2 with the open top providing ready access for introduction of the embryo or other biological material and also easy access for introduction and flushing of the treatment solutions being used.
The vessel is preferably generally oval in shape and includes a channel portion 3 formed in the bottom region 6 thereof. The channel region preferably includes dual raised portions of the bottom region 6 of the vessel which extend longitudinally and include a restriction 4 formed toward the centre thereof. In this manner, the integrally formed channel provides a preliminary flow path for introduced treatment solutions which can be introduced into the reservoir and flushed along the channel from one end 8 to the other end 8. As more treatment solution is introduced into the reservoir the flew path moves over the channel into the bulk of the reservoir. The provision of the channel creates two sub-reservoirs 7 at either end of the vessel, communicating with and being formed integrally to the channel. The channel has a restriction 4 at or near the middle or centre thereof, which is dimensioned to resist passage of a human embryo or resist passage of whatever biological material intended for use. The restriction is most preferably dimensioned to resist, but not totally prohibit passage of a human embryo, but dimensioned to encourage the human embryo to remain within one of the sub-reservoirs where the action of surface tension and fluid dynamics encourages the embryo to remain at one or other of the sub-reservoirs, rather than moving from one sub-reservoir to the other as treatment liquids are flushed into the reservoir, and through the channel.
As fluid is drawn through the channel away from the sub-reservoir containing the embryo, the dimensions and cross-section of the channel restrict fluid movement in a particular region in the manner of a “dead pocket”. This region is on the base of vessel, in the vicinity of the gradual transition of wider sub-reservoir to narrower channel. This configuration allows the captive embryo to be retained at one end and minimises treatment solution needed to flush the embryo.
The reservoir is preferably symmetric—when the fluid withdrawal position is further away from the centreline of the channel than the restricted flow region described above (i.e.—actually in the sub-reservoir), the surface tension retaining fluid in the channel overcomes the surface tension joining the fluid to the withdrawal position as it is further away. The fluid eventually ‘breaks’, leaving a residual volume in the channel, containing the embryo. The residual volume is sufficiently small for rapid vitrification of the embryo.
The geometry of the holding vessel contributes to the flow characteristics of fluid movement and contribute toward control and manipulation of the embryo. For example, withdrawal of fluid too close to the channel, will risk draining the channel totally and loosing the embryo. Conversely, if fluid is withdrawn too far away from the channel, too much fluid can be left behind which can compromise rapid vitrification. Moreover, the rate of fluid withdrawal is important to ensure there is a “dead pocket”.
The floor of the sub-reservoirs preferably slope towards the channel to enable gravity to assist locating the embryo in the “dead pocket”. The slope should preferably not continue into the channel, but most preferably has a flatter base to prevent the embryo from entering the channel proper.
Referring to
In addition, the provision of a divot 14 allows for maximum removal of previous irrigation solutions and in particular, the divot 14 allows a highly controlled volume of leftover solution surrounding the captured biological material or embryo and therefore allows the reliable dispensation of a minimal amount of vitrification solution whilst knowing the precise position of the embryo of biological material within the apparatus.
Diameter of the withdrawal tip may contribute to the fluid bridging between the sides of the sub-reservoir and assisting fluid removal and flow patterns.
In this manner, the vessel of the invention provides for the highly controlled handling and manipulation of human embryos and the like, where the human embryo can be carefully placed into the vessel at one or other of the sub-reservoirs 7 or directly into the divot. Once the embryo is carefully positioned in the sub-reservoir or divot, the treatment fluids can be then carefully introduced into the vacant sub-reservoir which is not occupied by the biological material and with the gentle flushing of fluid from an unoccupied or vacant sub-reservoir through the channel to the occupied sub-reservoir, the treatment fluids can be withdrawn and the subsequent treatment fluids are then introduced into the unoccupied sub-reservoir and gently flushed through to the occupied sub-reservoir. In this manner, a plurality of flushing operations can be executed with minimal disturbance of the embryo which is held captive in the occupied sub-reservoir or divot using the vacant sub-reservoir to add or withdraw fluids.
In a particularly preferred embodiment, the treatment fluids can be graduated such that one continuous flushing operation can be executed using a gradation of treatment fluids so as to minimise trauma and toxic shock to the embryo held captive in a first sub-reservoir. In this way, the embryo is subject to only one act of physical flushing, thereby greatly minimising any disturbance of the embryo. The configuration of the channel and restrictions is adapted to encourage flushing of fluids therethrough, whilst minimising any unnecessary turbulence which could potentially buffet and physically damage the embryo held captive in the first sub-reservoir.
The treatment fluids preferably contain gradually increasing non-permeating cryoprotectants and permeating cryoprotectants selected from Ethylene Glycol (EG), Dimethyl Sulphoxide (DMSO), Glycerol, disaccharides, trehalose and sucrose which are specifically adapted to enhance or encourage the sinking of the embryo or biological material to the bottom of the vessel. This enhances maximum drainage from the vessel and retention of minimal irrigation solution prior to vitrification or freezing, thereby enhancing the vitrification or freezing step. In addition, by ensuring the biological sample the embryo rapidly sinks to the bottom of the vessel, the chances of the biological material or embryo inadvertently escaping the vessel is minimised.
The vessel is preferably formed of a material having a high degree of thermal diffusivity to ensure fast cooling rate. In addition, the material forming the vessel is preferably biologically inert to minimise any possible contamination of the biological material. When the treatment liquids have all been removed, the vessel is adapted for vitrifying by placement in liquid nitrogen or the like, such that the captive embryo is itself vitrified rapidly by the high thermal conductivity and diffusivity of the vessel materials. In this way, the positioning of the embryo in the sub-reservoir at the bottom of the vessel, allows the vessel to be placed in liquid nitrogen, such that the liquid nitrogen has maximum thermal transmission directly to the embryo, whilst quarantining the embryo from any direct contact with the liquid nitrogen or other vitrification medium per se. Once the vitrification process is accomplished, the vessel and captive (now vitrified) embryo, can be removed from the liquid nitrogen and the vessel stored in a vitrified state awaiting thawing and use of the captive embryo, or alternative biological material.
An additional advantage of the vessel of the invention, particularly the vessel including the optional provision of divots and the minimal vitrification fluid used in the cooling process involves thawing, where thawing of the frozen biological material within the vessel of the invention can be accomplished rapidly with minimal disruption, due to the minimal amount of solution surrounding the biological material as achieved by the provision of the small divot or divots. The staled vessel of the invention can be placed directly into a warm, solution to achieve rapid and controlled thawing whilst maintaining maximum viability of the biological sample.
The vessel may be provided with a dedicated holder 15 as shown in
In order to maximise the versatility of the vessel and apparatus of the invention, the vessel and/or holder are preferably provided with a cap or lid 9, variations of the cap or lid being shown in
The lid is preferably formed integral to the vessel holder as shown in
Sealing can be either mechanical seal as describe above or chemical heat seal as shown in
The apparatus of the invention also includes a physical region thereof for the provision of a bar code or other identifying indicia whereby the indicia platform 10 allows the ready and secure identification of the vitrified embryo or other item of biological material. The vessel thereby provides maximum security and identification for a given human embryo, particularly as the biological material in question undergoes effectively one handling step only during the whole process post harvesting, through to vitrification and thawing. In this manner, the embryo has little or no chance of being mislabelled or misidentified during multiple steps and processes required for preparation and vitrification as the embryo never leaves the confines of the vessel once the treatment commences.
In another aspect the invention provides a cryopreservation apparatus where reference to
The cassettes are adapted for placement in a loader 16 as shown in
An alternative storage is shown in
The tank storage concept has advantages over current systems by:
The apparatus and in particular the vessel component of the invention lends itself to automation where the vessels can be automatically handled by suitable automated apparatus such that the array of vessels provided in an automated example of the invention, can, once the embryos have been carefully positioned into the vessel, then allow the full automation of the vitrification/freezing preparations and vitrification/freezing steps and the subsequent vitrifying/freezing and storage of a plurality of embryos to be fully automated without the requirement for the embryo to be moved, or requirement for individual monitoring or handling during any of the subsequent steps.
In another aspect the invention provides a semi automated device including provision for one or a plurality of the vessels as previously described wherein the apparatus includes a means to irrigate the captive biological material with pre-freezing or vitrification treatment solutions and fluidics to prepare the captive biological material for vitrification.
The vessel of the invention also finds various other uses including:
The full automation of the in vitro fertilisation preparation of vitrified embryos is expected to provide substantial improvements to viability of the rendered embryos, thereby maximising the viability of embryos once thawed and consequently maximising the chance of success and pregnancy to recipients of embryos provided by way of the apparatus and methods of the invention.
In addition to the apparatus the invention also provides a range of methods for the handling of biological materials as described.
In another aspect the invention provides a method of cryopreservation of biological materials comprising the steps of introducing a selected biological material into the reservoir region of a vessel as previously described for capture in the channel region thereof;
In the most particularly preferred embodiment where the apparatus includes the optional provision of one or a plurality of divots positioned within the intermediate restriction a typical protocol would consist of moving the embryo of biological material from a series of vitrification media to the final and most active solution. The media composition and time spent in each solution may be as follows:
Listed below are examples of variations in protocol of cryopreservation of biological material using the described apparatus.
Protocol of cryopreservation of biological material comprising of:
An alternative protocol is provided, without the removal of vitrification solution 2 as follows:
In addition, a protocol involving the addition of non-permeating cryoprotectant to the cryobase/vitrification solution 1, is provided as follows:
In addition, a protocol involving a single vitrification solution gradually added, is provided as follows:
In another aspect the invention provides a method for pre-vitrification treatment of a biological material, said method comprising the steps of:
In another aspect the invention provides a method of thawing a vitrified biological material, said method comprising the steps of:
In a further aspect the invention provides a method of storing a cryopreservation biological material comprising the steps of:
The methods of the invention lend themselves to a high degree of automation where the methods can be executed in automated apparatus and devices such that a plurality of embryos or other biological material can be processed simultaneously. The particular features of the invention allow for a high number of embryos or other biological material samples to be manually introduced into the vessels of the invention.
Once the individual samples of biological material have been introduced into a dedicated vessel and the vessels installed in the automated apparatus as previously described, the whole process of preparation for vitrification can be totally automated and monitored such that a large number of biological samples can be competently processed and vitrified in a seamless single-step operation.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive:
The present application claims priority from U.S. Provisional Patent Application No. 61/349,296 the content of which is incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4683058 | Lyman et al. | Jul 1987 | A |
| 5026342 | Hammerstedt et al. | Jun 1991 | A |
| 5261870 | Hammerstedt et al. | Nov 1993 | A |
| 5894733 | Brodner | Apr 1999 | A |
| 6000603 | Koskenmaki et al. | Dec 1999 | A |
| 6176089 | Bouche | Jan 2001 | B1 |
| 6337205 | Wisniewski | Jan 2002 | B1 |
| 6408878 | Unger et al. | Jun 2002 | B2 |
| 6500608 | Forest et al. | Dec 2002 | B2 |
| 6503698 | Dobrinsky et al. | Jan 2003 | B1 |
| 6514216 | Inoue et al. | Feb 2003 | B2 |
| 6519954 | Prien et al. | Feb 2003 | B1 |
| 6717182 | Tagami et al. | Apr 2004 | B1 |
| 6773877 | Fahy | Aug 2004 | B2 |
| 6793753 | Unger et al. | Sep 2004 | B2 |
| 6818395 | Quake et al. | Nov 2004 | B1 |
| 6838235 | Gardner et al. | Jan 2005 | B2 |
| 6899137 | Unger et al. | May 2005 | B2 |
| 6911345 | Quake et al. | Jun 2005 | B2 |
| 6929030 | Unger et al. | Aug 2005 | B2 |
| 6982172 | Yang et al. | Jan 2006 | B2 |
| 7040338 | Unger et al. | May 2006 | B2 |
| 7052545 | Quake et al. | May 2006 | B2 |
| 7087370 | Forest et al. | Aug 2006 | B2 |
| 7094601 | Toner et al. | Aug 2006 | B2 |
| 7144616 | Unger et al. | Dec 2006 | B1 |
| 7169314 | Unger et al. | Jan 2007 | B2 |
| 7195670 | Hansen et al. | Mar 2007 | B2 |
| 7216671 | Unger et al. | May 2007 | B2 |
| 7217321 | Hansen et al. | May 2007 | B2 |
| 7244402 | Hansen et al. | Jul 2007 | B2 |
| 7250128 | Unger et al. | Jul 2007 | B2 |
| 7278278 | Wowk et al. | Oct 2007 | B2 |
| 7306672 | Hansen et al. | Dec 2007 | B2 |
| 7316896 | Kuwayama et al. | Jan 2008 | B2 |
| 7326296 | Quake et al. | Feb 2008 | B2 |
| 7435582 | Zimmermann | Oct 2008 | B2 |
| 7459022 | Hansen et al. | Dec 2008 | B2 |
| 20010020636 | Koskenmaki et al. | Sep 2001 | A1 |
| 20010029983 | Unger et al. | Oct 2001 | A1 |
| 20010033796 | Unger et al. | Oct 2001 | A1 |
| 20010054778 | Unger et al. | Dec 2001 | A1 |
| 20020009704 | Yang et al. | Jan 2002 | A1 |
| 20020025529 | Quake et al. | Feb 2002 | A1 |
| 20020029814 | Unger et al. | Mar 2002 | A1 |
| 20020144738 | Unger et al. | Oct 2002 | A1 |
| 20020145231 | Quake et al. | Oct 2002 | A1 |
| 20030019833 | Unger et al. | Jan 2003 | A1 |
| 20030061687 | Hansen et al. | Apr 2003 | A1 |
| 20030096310 | Hansen et al. | May 2003 | A1 |
| 20030113706 | Forest et al. | Jun 2003 | A1 |
| 20030124548 | Hatzis et al. | Jul 2003 | A1 |
| 20030154729 | Prien et al. | Aug 2003 | A1 |
| 20040000901 | Sui | Jan 2004 | A1 |
| 20040115731 | Hansen et al. | Jun 2004 | A1 |
| 20040259072 | Kuwayama et al. | Dec 2004 | A1 |
| 20050014175 | Quake | Jan 2005 | A1 |
| 20050062196 | Hansen et al. | Mar 2005 | A1 |
| 20050106554 | Palecek et al. | May 2005 | A1 |
| 20050112882 | Unger et al. | May 2005 | A1 |
| 20050147992 | Quake et al. | Jul 2005 | A1 |
| 20050166980 | Unger et al. | Aug 2005 | A1 |
| 20050178317 | Quake et al. | Aug 2005 | A1 |
| 20050205005 | Hansen et al. | Sep 2005 | A1 |
| 20050226742 | Unger et al. | Oct 2005 | A1 |
| 20050229839 | Quake et al. | Oct 2005 | A1 |
| 20050250088 | Boldt | Nov 2005 | A1 |
| 20060019263 | Quake et al. | Jan 2006 | A1 |
| 20060046243 | Stachecki et al. | Mar 2006 | A1 |
| 20060054228 | Unger et al. | Mar 2006 | A1 |
| 20060134596 | Sjogren et al. | Jun 2006 | A1 |
| 20060172408 | Quake et al. | Aug 2006 | A1 |
| 20060177852 | Gabbai | Aug 2006 | A1 |
| 20060188865 | Fuhr | Aug 2006 | A1 |
| 20060196409 | Quake et al. | Sep 2006 | A1 |
| 20060234204 | Forest et al. | Oct 2006 | A1 |
| 20060246414 | Chang et al. | Nov 2006 | A1 |
| 20070024903 | Kitahara et al. | Feb 2007 | A1 |
| 20070037271 | Huang et al. | Feb 2007 | A1 |
| 20070059494 | Unger et al. | Mar 2007 | A1 |
| 20070087321 | Pribenszky et al. | Apr 2007 | A1 |
| 20070169686 | Quake et al. | Jul 2007 | A1 |
| 20070209572 | Hansen et al. | Sep 2007 | A1 |
| 20070209574 | Hansen et al. | Sep 2007 | A1 |
| 20070249038 | Adamo et al. | Oct 2007 | A1 |
| 20080026460 | Palecek et al. | Jan 2008 | A1 |
| 20080038155 | Chian et al. | Feb 2008 | A1 |
| 20080050717 | Brower, Jr. et al. | Feb 2008 | A1 |
| 20080050815 | Sher et al. | Feb 2008 | A1 |
| 20080083177 | Tiberi et al. | Apr 2008 | A1 |
| 20080220520 | Palecek et al. | Sep 2008 | A1 |
| 20080236669 | Unger et al. | Oct 2008 | A1 |
| 20080268492 | Mullen et al. | Oct 2008 | A1 |
| 20090004296 | Gabbai | Jan 2009 | A1 |
| 20090029340 | Gabbai | Jan 2009 | A1 |
| 20090081305 | Gabbai | Mar 2009 | A1 |
| 20090081782 | Yoon et al. | Mar 2009 | A1 |
| 20090093054 | Sjogren et al. | Apr 2009 | A1 |
| 20090120106 | Chin | May 2009 | A1 |
| 20090123992 | Chin | May 2009 | A1 |
| 20090123996 | Chin | May 2009 | A1 |
| 20090126373 | Burg | May 2009 | A1 |
| 20090130753 | Bowermaster et al. | May 2009 | A1 |
| 20090186405 | Chin | Jul 2009 | A1 |
| 20090202978 | Shaham | Aug 2009 | A1 |
| 20090239207 | Leese et al. | Sep 2009 | A1 |
| 20090253613 | Gabbai | Oct 2009 | A1 |
| 20090255938 | Fuja | Oct 2009 | A1 |
| 20090305224 | He et al. | Dec 2009 | A1 |
| 20100015697 | Junger et al. | Jan 2010 | A1 |
| 20100212331 | Critser et al. | Aug 2010 | A1 |
| 20100267007 | Gabbai | Oct 2010 | A1 |
| 20100281886 | Shaham et al. | Nov 2010 | A1 |
| 20100297600 | Cecchi | Nov 2010 | A1 |
| 20100317108 | Stojanov | Dec 2010 | A1 |
| 20110207112 | Burbank et al. | Aug 2011 | A1 |
| 20130137080 | Henderson et al. | May 2013 | A1 |
| 20130204076 | Han et al. | Aug 2013 | A1 |
| Number | Date | Country |
|---|---|---|
| 202006017103 | Mar 2007 | DE |
| 2002543041 | Dec 2002 | JP |
| 9908513 | Feb 1999 | WO |
| 0021365 | Apr 2000 | WO |
| 02085110 | Oct 2002 | WO |
| 2005032341 | Apr 2005 | WO |
| 2006097749 | Sep 2006 | WO |
| Entry |
|---|
| Yun Seok Heo et al, Controlled loading of cryprotectants (CPAs) to oocyte with linear and complex CPA profiles on a microfluidic platform, Lab Chip, vol. 11, No. 1, Oct. 21, 2011, p. 3530, 15 pages, XP055284596. |
| Li et al, Bulk vitrification of human embryonic stem cells, Human Reproduction, vol. 23, No. 2, Dec. 14, 2007, pp. 358-364. |
| Chen et al. Vitrification of mouse oocytes using closed pulled straws (CPS) achieves a high survival and preserves good patterns of meiotic spindles, compared with conventional straws, open pulled straws (OPS) and grids. Human Reproduction, 2001, V16(11), pp. 2350-2356. |
| Abe et al. Feasibility of a nylon-mesh holder for vitrification of bovine germinal vesicle oocytes in subsequent production of viable blastocysts. Biology of Reproduction, 2005, 72, pp. 1416-1420. |
| Matsumoto et al. Vitrification of large quantities of immature bovine oocytes using nylon mesh. Cryobiology, 2001, 42, pp. 139-144. |
| Park et al. Simple, efficient and successful vitrification of bovine blastocysts using electron microscope grids. Human Reproduction, 1999, vol. 14, No. 11, pp. 2838-2843. |
| Park et al. Ultra-rapid freezing of human multipronuclear zygotes using electron microscope grids. Human Reproduction, 2000, vol. 15, No. 8, pp. 1787-1790. |
| Dinnyes et al. High developmental rates of vitrified bovine oocytes following parthenogenetic activation, in vitro fertilization, and somatic cell nuclear transfer. Biology of Reproduction, 2000, 63, pp. 513-518. |
| Cryocane. www.coleparmer.com/buy/product/52491-thermo-scientific-cryocane-aluminum-300-fl-holds-6-vials-5015-0002.html#Specs; downloaded on Nov. 13, 2012, p. 1. |
| Cremades et al (2004). Experimental vitrification of human compacted morulae and early blastocysts using fine diameter plastic micropipettes. Human reproduction, v19(2), pp. 300-305. |
| Son and Tan (2009). Comparison between slow freezing and vitrification for human embryos. Expert Rev. Med. Devices, v6(1), pp. 1-7. |
| “Safe-Lock tubes 0.5 ml”. (Nov. 13, 2009, captured from PDF properties). Product brochure by Eppendorf. |
| Daigger product brouch to “Racks/Liquid Measures” (Mar. 6, 2009). pp. 14-19 plus appended snapshot for pub. date. |
| Vutyavanich et al, Closed-system solid surface vitrification versus slow programmable freezing of mouse 2-cell embryos, J Assist Reprod Genet (2009) 26, pp. 285-290. |
| Rall et al, Development of mouse embryos cryopreserved by vitrification, J. Reprod.Fert. (1987) 80, pp. 499-504. |
| Number | Date | Country | |
|---|---|---|---|
| 20190174743 A1 | Jun 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61349296 | May 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13700258 | US | |
| Child | 15192349 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15192349 | Jun 2016 | US |
| Child | 16272602 | US |
